Aequus Pharmaceuticals (CVE:AQS) Reaches New 12-Month Low – Should You Sell?

Aequus Pharmaceuticals Inc. (CVE:AQS)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 45000 shares. The stock had previously closed at C$0.01.

Aequus Pharmaceuticals Stock Down 50.0 %

The company has a market capitalization of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock’s fifty day moving average is C$0.01 and its 200 day moving average is C$0.02.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.